Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
Zeid Kayali,1 Warren N Schmidt2,3 1Division of Gastroenterology and Hepatology, University of Southern California, Los Angeles, CA, USA; 2Department of Internal Medicine and Research Service, Veterans Affairs Medical Center, Iowa City, IA, USA; 3Roy G and Lucille A Carver College of Medicine, Univer...
Saved in:
Main Authors: | Kayali Z (Author), Schmidt WN (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
by: Katarzyna Lipa, et al.
Published: (2018) -
Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
by: Katarzyna Lipa, et al.
Published: (2018) -
Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020) -
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
by: Harel Dahari, et al.
Published: (2016) -
Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
by: Rodolfo Sacco, et al.
Published: (2020)